Skip to content
Review Open access

Use of real-world evidence in the U.S. Food and Drug Administration and the European Medicines Agency approvals of oncology products supported by single-arm trials (2022-2025)

Aug 2026 · The Oncologist · Vol 31 · 0 citations · 20 references
Medicine

TL;DR

RWE is increasingly used to support oncology SATs and holds promise as supportive or contextual evidence in regulatory decision-making and methodological limitations commonly included small sample sizes, population heterogeneity, missing or unmeasured covariates, non-aligned outcome assessments, post-hoc design, and non-contemporaneous treatments.

Abstract

Abstract Introduction Regulatory interest in real-world evidence (RWE) to supplement single-arm trials (SATs) in oncology has increased, yet how the Food and Drug Administration (FDA) and European Medicines Agency (EMA) evaluate such evidence remains incompletely understood. Objective To comprehensively evaluate recent oncology approvals in which SATs were supported by RWE, characterizing regulatory feedback, methodological approaches, role of RWE in decision-making. Methods We reviewed FDA New Drug Applications and Biologics License Applications (NDAs/BLAs), and EMA Marketing Authorizations (MAAs) (January 2022-August 2025). Approvals were identified through publicly available FDA and EMA databases. Regulatory documents were screened using predefined RWE- and SAT-related keywords, with full-text review for data extraction. Results Among 883 original approvals (553 FDA, 330 EMA), 200 were oncology products (134 FDA, 66 EMA). Eighteen applications (7 FDA, 11 EMA) incorporated SATs supplemented by RWE, representing 15 unique products, predominantly for hematologic malignancies (53.3%). All 15 products included at least 1 RWE approach, and 8 used multiple approaches including historical clinical trial data and literature. Among 25 distinct RWE or observational approaches, 16 (64.0%) were retrospective cohort designs drawing on patient-level data from electronic health records (24.0%), disease (20.0%) or product registries (4.0%), or chart abstractions (28.0%). RWE primarily served as contextual/supportive evidence (only 2 use cases viewed as providing “substantial evidence”). Methodological limitations commonly included small sample sizes, population heterogeneity, missing or unmeasured covariates, non-aligned outcome assessments, post-hoc design, and non-contemporaneous treatments. Conclusions RWE is increasingly used to support oncology SATs and holds promise as supportive or contextual evidence in regulatory decision-making.

Read PDF

Similar papers

Review Open access Sep 2026

PRO‑CTCAE in Oncology Drug Evaluation: Cross-Agency Review of Regulatory and Health Technology Assessment Decision-Making in the United States and Europe.

Harmonized, cross-agency guidance on PRO-CTCAE item selection, endpoint definition, analysis, and presentation may help support its consistent and meaningful use in future oncology submissions and regulatory and HTA decision-making.

E. Basch, Matthew Reaney, J. Roydhouse et al. · 0 citations
Review Open access Aug 2026

Drug exposure definitions reported in real-world evidence studies on oncology medicines in patients with colorectal cancer: a scoping review

Background Defining, measuring, and reporting exposure in real-world data are important for the valid generation and interpretation of real-world evidence (RWE). This is especially challenging for oncology medicines, due to complicated treatment regimens and adjustments in dose and/or schedule. This scoping review aims...

J. E. M. van Dommelen, H. Gardarsdottir, T. Egberts et al. · 0 citations
Review Open access Sep 2026

Orphan drug regulation: a global comparison of the United States Food and Drug Administration, European Medicines Agency, and Japanese Pharmaceuticals and Medical Devices Agency approaches.

A comparative review of orphan drug policies and designation criteria implemented by the US Food and Drug Administration, the European Medicines Agency, and Japan's Pharmaceuticals and Medical Devices Agency is performed, assessing their influence on development, approval, and access.

Robinraja Elango, Russell Martin, S. Mutta · 0 citations
Review Open access Aug 2026

Recommendations for generating real-world evidence with regulatory-grade relevance and reliability

A purpose-oriented framework clarifying the levels of relevance and reliability required according to specific regulatory objectives is proposed, and practical recommendations for generating regulatory-grade RWE that meaningfully informs regulatory decision-making while complementing conventional clinical trials are pr...

Yasutoshi Sakamoto, H. Bando, Yoshihiro Aoyagi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.